The Design, Analysis and Testing of Low Cost Dual Deployable Solar Panels for Small Satellite Missions

The National Science Foundation (NSF) funded university small satellite mission, Space Weather Atmospheric Reconfigurable Multiscale Experiment (SWARM-EX) is designed to address outstanding aeronomy and space weather questions while demonstrating swarm behavior in constellations of six to twelve 3U CubeSats. SWARM-EX is limited in power, which requires the use of dual-deployable solar panels in order to maximize the number of solar cells powering the small satellite. Commercial off the shelf (COTS) dual-deployable solar panel options tend to be expensive, necessitating the creation of custom-built, dual-deployable solar panels. The design of the dual-deployable solar panels is constrained in volume, manufacturability, and survivability of the launch conditions. In the stowed launch configuration, the full smallsat assembly must fit in an 88 mm by 326.1 mm by 9 mm space. The dual-deployable solar panel assembly must also be able to withstand the vibroacoustic launch environment. The launch environment requires withstanding a vibroacoustic load of 10 Grms for one minute in each axis. The solar panel assembly underwent testing in order to ensure the system operates as expected during the mission. Deployment testing will be conducted, and vibrational testing is planned for six months before launch

Effects of nordic walking exercise on gait, motor/non-motor symptoms, and serum brain-derived neurotrophic factor in individuals with Parkinson's disease

ObjectiveThe primary purpose of this study was to investigate the immediate and long-term effects of Nordic Walking (NW) exercise on walking function, motor/non-motor Parkinson's Disease (PD) symptoms, and serum brain-derived neurotrophic factor (BDNF) in persons with idiopathic PD.MethodsTwelve community-dwelling participants with mild to moderate idiopathic PD and varied degrees of gait dysfunction were recruited for this prospective, repeated measures design that examined clinical measures and BDNF levels at baseline (T0), post-intervention (T1) and 3-month follow-up (T2). Participants engaged in 6 weeks of supervised NW exercise training with individualized instruction, followed by 14 weeks of independent NW exercise with remote coaching. Outcome measurements included daily step counts, 6-Minute Walk Test (6-MinWT), 10-Meter Walk Test (10MWT), spatiotemporalparameters, Timed Up and Go Test (TUG), dual-task TUG, Revised-Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Revised-Freezing of Gait Questionnaire, MDS-Nonmotor Symptom scale (NMS), Parkinson's Fatigue Scale, and serum BDNF levels. The Friedman test with post hoc Wilcoxon sign-ranked pairwise comparisons were used to compare baseline to T1, baseline to T2, and T1 to T2 timepoints with a Benjamini-Hockberg correction applied.ResultsStatistically significant improvements found post-training and retained at 3-month follow-up included 6-MinWT, daily step count, 10mWT, MDS-UPDRS, and TUG with effect sizes of 0.57 to 1.03. Serum BDNF at T2 was significantly greater than T0 and T1. Although no statistically significant improvements were observed in the MDS-NMS, 9 of 12 participants had improved non-motor symptoms. There was good adherence, sustained independent exercise engagement, and no adverse events over the 5-month study duration.ConclusionsThis study demonstrated that NW exercise was a safe, feasible, and sustainable mode of aerobic exercise for this sample of participants with varied Parkinson's disease duration and severity. Following an individualized and progressive NW training intervention, significant improvements in walking function, daily activity level, and motor function were observed. Following the supervised NW training phase, independent three-month engagement in NW exercise was sustained with long-term retention of these clinical improvements and an increase in serum BDNF levels over this five-month NW exercise trial.ImpactNordic walking exercise may be a safe, feasible and sustainable mode of independent exercise for improving daily ambulatory activity, gait and motor function, and serum BDNF in individuals with mild to moderate PD with varied gait abilities.Clinical Trials Registry ID20-101-

Effects of a Vegetarian Diet on Recurrent Myocardial Infarction Rates

Each year, approximately 790,000 people in the United States will suffer from a myocardial infarction (MI), and 210,000 of those cases will not be for the first time (Centers for Disease Control and Prevention, 2017). The World Health Organization defines a myocardial infarction as “myocardial cell necrosis due to significant and sustained ischaemia” (Mendis et al., 2010). A major risk factor for MI is consuming a diet high in saturated fat, and trans fat which are all commonly found in processed foods and animal fats (Centers for Disease Control and Prevention, 2017). The purpose of this Evidence Based Practice brief is to compare rates of MI in patients with a history of MI that consume a vegetarian diet versus those with a history of MI that do not consume a vegetarian diet. These findings will be used to educate patients on non-pharmaceutical ways to reduce their risk of a recurrent myocardial infarction from occurring. The information obtained from this review will be used in the planning and intervention phases of the nursing process

Nordic Walking Exercise Effects on Walking Function, Motor/Nonmotor Symptoms and Biomarkers in Individuals with Parkinson’s Disease

PURPOSE: The primary purpose of this study was to investigate the immediate and long-term effects of Nordic Walking (NW) exercise on walking function, motor/non-motor Parkinson’s Disease (PD) symptoms, and serum brain-derived neurotrophic factor (BDNF) in persons with idiopathic PD. SUBJECTS: Twelve participants with idiopathic PD, including 8 male, 4 female; age 46-82 years, Hoehn & Yahr stages I-III (subtypes: 7=postural/gait instability, 3=tremor dominant, 2=indeterminate); wide range of disease severity scores at baseline. METHODS AND MATERIALS: Twelve community-dwelling participants with mild to moderate idiopathic PD and varied degrees of gait dysfunction were recruited for this prospective, repeated measures design that examined clinical measures and BDNF levels at baseline (T0), post-intervention (T1) and 3-month follow-up (T2). Participants engaged in 6 weeks of supervised NW exercise training with individualized instruction, followed by 14 weeks of independent NW exercise with remote coaching. Outcome measurements included daily step counts, 6-Minute Walk Test (6-MinWT), 10-Meter Walk Test (10MWT), spatiotemporal parameters, Timed Up and Go Test (TUG), dual-task TUG, Revised-Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Revised-Freezing of Gait Questionnaire, MDS-Nonmotor Symptom scale (NMS), Parkinson’s Fatigue Scale, and serum BDNF. ANALYSES: The Friedman test with post hoc Wilcoxon sign-ranked pairwise comparisons were used to compare baseline to T1, baseline to T2, and T1 to T2 timepoints with a Benjamini-Hockberg correction applied. RESULTS: Statistically significant improvements found post-training and retained at 3-month follow-up included 6-MinWT, daily step count, 10mWT, MDS-UPDRS, and TUG with effect sizes of 0.57 to 1.03. Serum BDNF at T2 was significantly greater than T0 and T1. Although no statistically significant improvements were observed in the MDS-NMS, 9 of 12 participants had improved non-motor symptoms. There was good adherence, sustained independent exercise engagement, and no adverse events over the 5-month study duration. CONCLUSIONS: This study demonstrated that NW exercise was a safe, feasible, and sustainable mode of aerobic exercise for this sample of participants with varied Parkinson’s disease duration and severity. Following individualized and progressive NW training, independent NW walking exercise and sustained improvements in walking function, activity level, motor function, and increased serum BDNF levels were observed. Nordic walking exercise may be a safe, feasible and sustainable mode of independent exercise for improving daily ambulatory activity, gait and motor function, and serum BDNF in individuals with mild to moderate PD with varied gait abilities

Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations

We report the first experimental measurements of Ramachandran Ψ-angle distributions for intrinsically disordered peptides: the N-terminal peptide fragment of tumor suppressor p53 and its P27S mutant form. To provide atomically detailed views of the conformational distributions, we performed classical, explicit-solvent molecular dynamics simulations on the microsecond time scale. Upon binding its partner protein, MDM2, wild-type p53 peptide adopts an α-helical conformation. Mutation of Pro27 to serine results in the highest affinity yet observed for MDM2-binding of the p53 peptide. Both UV resonance Raman spectroscopy (UVRR) and simulations reveal that the P27S mutation decreases the extent of PPII helical content and increases the probability for conformations that are similar to the α-helical MDM2-bound conformation. In addition, UVRR measurements were performed on peptides that were isotopically labeled at the Leu26 residue preceding the Pro27 in order to determine the conformational distributions of Leu26 in the wild-type and mutant peptides. The UVRR and simulation results are in quantitative agreement in terms of the change in the population of non-PPII conformations involving Leu26 upon mutation of Pro27 to serine. Finally, our simulations reveal that the MDM2-bound conformation of the peptide is significantly populated in both the wild-type and mutant isolated peptide ensembles in their unbound states, suggesting that MDM2 binding of the p53 peptides may involve conformational selection. © 2011 American Chemical Society